Novo Nordisk’s Phase 3 ZEUS Trial Misses Cardiovascular Endpoint for Ziltivekimab

Novo Nordisk today announced headline results from the ZEUS cardiovascular outcomes phase 3 trial. While ziltivekimab demonstrated target engagemen...

August 04, 2026 | Tuesday | News
SciSparc Highlights NeuroThera’s Quantum Analytics Milestone for Clinical Trial Data

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”),  announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a ...

August 04, 2026 | Tuesday | News
From Documentation to Detection: How AI Is Changing the APP Role

Artificial intelligence is transforming the role of advanced practice providers (APPs) by streamlining documentation, simplifying clinical workfl...

August 03, 2026 | Monday | Interaction
Massive Bio Partnered with GELL to Advance AI-Driven Oncology Research Across Latin America and the U.S.

-Massive Bio, a global leader in artificial intelligence-driven solutions for oncology, clinical trial matching, and patient navigation, and the Latin Am...

July 29, 2026 | Wednesday | News
Idorsia Partners with Jamjoom Pharma to Expand QUVIVIQ Commercialization Across Saudi Arabia and the Levant

Exclusive agreement with Jamjoom Pharma covers commercialization and distribution of QUVIVIQ™ (daridorexant) in Saudi Arabia and the Levant region ...

July 28, 2026 | Tuesday | News
Fresenius Launches €200 Million Venture Fund to Invest in Healthcare Innovation

The issuer is solely responsible for the content of this announcement. Fresenius is further expanding its access to innovation networks through its own co...

July 27, 2026 | Monday | News
Dana-Farber, OSUCCC–James and IBCRF Launch Collaborative Research Initiative for Metastatic Inflammatory Breast Cancer

In a significant move to advance the treatment of patients with inflammatory breast cancer (IBC), Dana-Farber Cancer Institute, The Ohio State Univ...

July 20, 2026 | Monday | News
Ascletis Selected Oral ASC30 and ASC48 Combination for Obesity Clinical Development

ASC48 is a potentially first-in-class oral small molecule GIPR agonist. - ASC48 demonstrated an EC50 of 1 pM in the hGIPR cAMP activation assay, exhibit...

July 17, 2026 | Friday | News
Sapphiros Secures BARDA-Backed RRPV Agreement to Advance Portable Molecular Diagnostics

Multi-year program supports development of disposable molecular diagnostic platforms for point-of-care, field-use, and emergency response settings  ...

July 16, 2026 | Thursday | News
Mesoblast Completes Target Enrollment in Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases,  announced that it has achieved ...

July 15, 2026 | Wednesday | News
Zelluna Doses First Patient in Phase 1 Trial of ZI-MA4-1 TCR-NK Cell Therapy

First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation Trust ZI-MA4-1 is the world’s first MAGE-A4-targe...

July 15, 2026 | Wednesday | News
What Future UK Regulation of AI in Healthcare Looks Like Now

  While we will need to wait for the National Commission into the Regulation of AI in Healthcare's recommendations later this summer, and then the MH...

July 14, 2026 | Tuesday | Expert Opinion
Warburg Pincus Set to Acquire Pantherx Rare in Deal Valued at Over US$7 Billion

Private equity firm Warburg Pincus is reportedly close to acquiring Pantherx Rare, a leading US specialty pharmacy focused on rare and orphan diseases, in ...

July 13, 2026 | Monday | News
Vivani Medical Signs Agreement with Novo Nordisk to Evaluate NPM-139 Obesity Implant

Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative biopharmaceutical company specializing in the development of innovative dr...

July 13, 2026 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close